|
Puertas B, Gonzalez-Calle V, Sureda A, Moreno MJ, Oriol A, Gonzalez E, Rosinol L, Lopez J, Escalante F, Martinez-Lopez J, Carrillo E, Clavero E, Rios-Tamayo R, Rey-Bua B, Gonzalez-Rodriguez AP, Dourdil V, De Arriba F, Gonzalez S, Perez-de-Oteyza J, Hernandez MT, Garcia-Mateo A, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, Ocio EM, Mateos MV. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. Haematologica. 2023 Oct 1;108(10):2753-2763. doi: 10.3324/haematol.2022.282490. PubMed PMID: 37102598; PubMed Central PMCID: PMC10542845.
AÑO: 2023; IF: 8.2
|
37102598
|
Mateos MV, Martinez-Lopez J, Rodriguez Otero P, Gonzalez-Calle V, Gonzalez MS, Oriol A, Gutierrez NC, Rios-Tamayo R, Rosinol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Inigo Rodriguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernandez MT, Lopez Jimenez J, Reinoso-Segura M, Garcia Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Blade J, Lahuerta JJ, San-Miguel JF; Spanish Myeloma Group (GEM-Pethema). Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J Clin Oncol. 2024 Sep 20;42(27):3247-3256. doi: 10.1200/JCO.23.02771. Epub 2024 Jul 22. PubMed PMID: 39038268; PubMed Central PMCID: PMC11404760.
AÑO: 2024; IF: 41.9
|
|
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosinol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Blade J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Espanol de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatias Malignas) cooperative study group. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression. Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3. PubMed PMID: 38684670; PubMed Central PMCID: PMC11059156.
AÑO: 2024; IF: 11.6
|
|
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabanas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosinol L, Blade J, Cedena MT, Puig N, Paiva B; PETHEMA/GEM Cooperative Group. Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma. J Clin Oncol. 2025 Jan 10;43(2):125-132. doi: 10.1200/JCO.24.00635. Epub 2024 Oct 1. PubMed PMID: 39353166.
AÑO: 2025; IF: 41.9
|
|
Monreal Bernal A, Berenguer Piqueras M, Ortiz Salvador P, Suarez Terron M, Bataller Alfonso A, Delgado Palacio S, Senent Peris ML, Roig Pellicer M, Villalba Valenzuela A, Benet Campos C, Espinosa Arnandi C, Fernandez Poveda E, Salido Fierez E, Rodenas Quinonero I, de Arriba de la Fuente F, Ortiz Andrade J, Marco Ayala J, Lozano ML, Ortuno FJ. Visceral leishmaniasis in heavily pretreated multiple myeloma patients a case series of 17 patients from the Mediterranean Coast of Spain. Ann Med. 2025 Dec;57(1):2514075. doi: 10.1080/07853890.2025.2514075. Epub 2025 Jun 5. PubMed PMID: 40470770; PubMed Central PMCID: PMC12143001.
AÑO: 2025; IF: 4.3
|